)
Visual
test
PolyPeptide Group
PolyPeptide Group (PPGN) investor relations material
PolyPeptide Group H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary12 Aug, 2025
Executive summary
Revenue grew 24% year-over-year in H1 2025, reaching €167.1 million, mainly from commercial and metabolic therapeutics, with strong cash flow from disciplined working capital and customer prepayments.
EBITDA increased to €4.4 million, supported by higher sales but offset by increased costs and investments.
Expanded revolving credit facility to €151 million, enhancing financial flexibility for capacity expansion.
Capacity expansion projects in Belgium, Sweden, and France are progressing on schedule, targeting full utilization by year-end.
2025 guidance revised upward and 2028 midterm outlook confirmed.
Financial highlights
H1 2025 sales reached €167.1 million, up 23.7% year-over-year, driven by nearly €30 million growth in commercial business.
EBITDA increased by €14.5 million, with margin at 2.7% (up 0.5 ppt year-over-year).
Net result for the period: €-26.5 million, impacted by unfavorable FX revaluation.
Operating cash flow reached €49.7 million, with period-end cash at €76.7 million.
Net cash flow from investing activities was €-50.8 million, mainly due to capacity expansion.
Outlook and guidance
2025 revenue growth guidance revised to 13–20% at constant exchange rates, reflecting strong H1 momentum.
EBITDA margin for 2025 expected in the high single-digit to low double-digit range.
CapEx guidance increased to €100 million for 2025, reflecting accelerated customer demand.
2028 midterm guidance reconfirmed: double 2023 revenues, EBITDA margin approaching 25%, CapEx 15–20% of revenues.
Assess impact of unfavorable product mix.
Explain the drivers behind the 2028 EBITDA target.
How does PolyPeptide address supply chain matters?
Ultra-high capacity SPPS resin impact on output
ERP system cost peak and its financial implications
Generic GLP impact on peptide API market
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- BPT
H1 FY26 revenue hit $1B, with strong gas prices and LNG cargoes offsetting lower production. - CPAY
Record 2025 results and 2026 outlook driven by strong segment growth and capital deployment. - 032640
Net income surged 61.9% year-over-year, with strong wireless and enterprise growth. - LOT
A$76M equity raise supports Kayelekera ramp-up and Letlhakane development amid strong uranium demand. - SYM
Revenue up 29% to $630M, net income $13.36M, $22.3B backlog, strong cash, legal risks persist. - TENB
Record 2025 results with double-digit growth, strong cash flow, and expanding AI-driven platform. - DHX
Q4 2025 revenue down 10% YoY; FY 2026 guidance targets $118M–$122M revenue. - COHR
Q2 FY26 revenue up 17% to $1.69B, with strong EPS growth and robust datacenter demand. - ALGT
Q4 2025 saw record results and margin growth, with 2026 outlook boosted by Sun Country deal. - STC
Record bookings, strong cash flow, and margin expansion drive improved outlook.
Next PolyPeptide Group earnings date
H2 202512 Mar, 2026
PolyPeptide Group
Next PolyPeptide Group earnings date
H2 202512 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
PolyPeptide Group AG is a leading contract development and manufacturing organization (CDMO) specializing in the production of peptides and related molecules. The company provides services across the entire development spectrum, from initial peptide synthesis to commercial-scale manufacturing. PolyPeptide supports pharmaceutical and biotech companies with both proprietary and generic Good Manufacturing Practice (GMP)-grade peptides used in approved pharmaceutical products, drugs in clinical development, and in generic products. Additionally, it manufactures a variety of peptides used in cosmetic applications. The company is headquartered in Baar, Canton of Zug, Switzerland, and its shares are listed on the stock exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage